CAR‐T cells in first relapse of paediatric Down syndrome B‐cell acute lymphoblastic leukaemia: Oncologist perspectives
Year: 2026
Type: article
Study design: Observational Study
Abstract: Management of B-cell acute lymphoblastic leukaemia (B-ALL) in patients with Down syndrome (DS-ALL) is complicated by increased toxicity and relapse rates. For first relapse of DS-ALL, optimal management is uncertain. Chimeric antigen receptor T-cell (CAR-T) therapy offers an alternate approach for remission induction and/or definitive curative therapy, and recent reports suggest similar efficacy and tolerability in DS and non-DS patients. We distributed an international survey to paediatric oncologists treating DS-ALL querying opinions on therapy, monitoring and toxicity in this population. Among 89 respondents, 76%, 80% and 64% favoured definitive CAR-T therapy without intent for subsequent haematopoietic stem cell transplantation (HSCT) for early medullary relapse, early and late isolated extra-medullary relapse respectively. For late medullary relapse, 47% preferred definitive CAR-T whereas 51% chose definitive chemoimmunotherapy. Only a minority of respondents selected HSCT as a planned approach for any first relapse: 11%-15% for early relapse; 3%-5% for late relapse. The main perceived benefit of CAR-T therapy was its favourable toxicity profile. Overall, 56% and 77% of respondents felt that it should be considered standard of care for low and high-risk relapse of DS-ALL respectively. Survey responses suggest that developing guidelines to integrate use of CAR-T is warranted for first relapse in DS-ALL.
Source: British Journal of Haematology
DOI: 10.1111/bjh.70945
Authors: Jeremy D. Rubinstein(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft), Colleen Annesley(Conceptualization, Data curation), Deepa Bhojwani(Conceptualization, Data curation), Sara Ghorashian(Conceptualization, Data curation), Johann Hitzler(Conceptualization, Data curation), Rishi S. Kotecha(Conceptualization, Data curation), Joerg Krueger(Conceptualization, Data curation), Susana Rives(Conceptualization, Data curation), Anupam Verma(Conceptualization, Data curation), Sara Zarnegar‐Lumley(Conceptualization, Data curation), Nirali N. Shah(Conceptualization, Data curation, Investigation, Supervision, Writing – original draft), Karen R. Rabin(Conceptualization, Data curation, Investigation, Supervision, Writing – original draft)
Institutions: Cincinnati Children's Hospital Medical Center, University of Cincinnati, Seattle Children's Hospital, University of Washington, University of Southern California, Children's Hospital Los Angeles, Great Ormond Street Hospital, University of Toronto, The Hospital for Sick Children, The Kids Research Institute Australia, The University of Western Australia, Curtin University, Princess Margaret Hospital for Children, Perth Children's Hospital, Hospital Sant Joan de Déu Barcelona, Parc Sanitari Sant Joan de Déu, Rainbow Babies & Children's Hospital, Case Comprehensive Cancer Center, Case Western Reserve University, Northwestern University, Lurie Children's Hospital, National Institutes of Health, National Cancer Institute, Center for Cancer Research, University of California, San Francisco, University of California San Francisco Medical Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: Estudio piloto de la infusión de linfocitos T autólogos modificados genéticamente para expresar anti-CD19 en pacientes con leucemia o linfoma CD19+ resistente o refractario a tratamiento, G6021524880, Preventing Fatal Infections in Children with Down Syndrome During Treatment for Acute Lymphoblastic Leukemia
OpenAlex ID: W7236635551
